Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ)
CNY 7.86
(0.51%)
CNY 7.86
(0.51%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 364.17 Million CNY | -34.43% |
| 2022 | 548.98 Million CNY | -6.04% |
| 2021 | 584.29 Million CNY | 37.41% |
| 2020 | 425.21 Million CNY | -35.72% |
| 2019 | 661.49 Million CNY | -17.94% |
| 2018 | 806.07 Million CNY | -41.92% |
| 2017 | 1.38 Billion CNY | -1.1% |
| 2016 | 1.4 Billion CNY | 12.46% |
| 2015 | 1.24 Billion CNY | 14.17% |
| 2014 | 1.09 Billion CNY | 22.44% |
| 2013 | 892.69 Million CNY | 60.51% |
| 2012 | 556.15 Million CNY | 170.22% |
| 2011 | 205.81 Million CNY | 60.53% |
| 2010 | 128.2 Million CNY | 44.0% |
| 2009 | 89.03 Million CNY | 74.91% |
| 2008 | 50.9 Million CNY | 111.29% |
| 2007 | 24.09 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 86.54 Million CNY | -7.65% |
| 2024 Q3 | 78.59 Million CNY | -9.18% |
| 2024 Q1 | 93.71 Million CNY | 4.8% |
| 2023 FY | 359.96 Million CNY | -34.43% |
| 2023 Q1 | 65.01 Million CNY | -60.85% |
| 2023 Q2 | 104.34 Million CNY | 60.49% |
| 2023 Q4 | 89.42 Million CNY | -14.9% |
| 2023 Q3 | 105.08 Million CNY | 0.71% |
| 2022 Q4 | 166.07 Million CNY | 22.32% |
| 2022 FY | 548.98 Million CNY | -6.04% |
| 2022 Q1 | 123.34 Million CNY | -21.93% |
| 2022 Q2 | 123.81 Million CNY | 0.38% |
| 2022 Q3 | 135.76 Million CNY | 9.65% |
| 2021 Q2 | 157.17 Million CNY | 36.13% |
| 2021 Q1 | 115.45 Million CNY | -10.51% |
| 2021 FY | 584.29 Million CNY | 37.41% |
| 2021 Q4 | 157.97 Million CNY | 2.8% |
| 2021 Q3 | 153.67 Million CNY | -2.22% |
| 2020 FY | 425.21 Million CNY | -35.72% |
| 2020 Q4 | 129 Million CNY | -0.93% |
| 2020 Q3 | 130.22 Million CNY | 17.21% |
| 2020 Q2 | 111.1 Million CNY | 102.44% |
| 2020 Q1 | 54.88 Million CNY | -60.06% |
| 2019 FY | 661.49 Million CNY | -17.94% |
| 2019 Q3 | 179.42 Million CNY | 4.23% |
| 2019 Q4 | 137.4 Million CNY | -23.42% |
| 2019 Q2 | 172.13 Million CNY | -0.23% |
| 2019 Q1 | 172.52 Million CNY | 0.33% |
| 2018 FY | 806.07 Million CNY | -41.92% |
| 2018 Q1 | 273.2 Million CNY | -9.85% |
| 2018 Q4 | 171.95 Million CNY | -9.41% |
| 2018 Q3 | 189.8 Million CNY | 10.92% |
| 2018 Q2 | 171.11 Million CNY | -37.37% |
| 2017 Q4 | 303.05 Million CNY | -19.44% |
| 2017 Q1 | 329.82 Million CNY | -15.67% |
| 2017 Q2 | 378.82 Million CNY | 14.86% |
| 2017 Q3 | 376.19 Million CNY | -0.69% |
| 2017 FY | 1.38 Billion CNY | -1.1% |
| 2016 FY | 1.4 Billion CNY | 12.46% |
| 2016 Q1 | 278.11 Million CNY | -21.0% |
| 2016 Q4 | 391.09 Million CNY | -0.65% |
| 2016 Q2 | 340.46 Million CNY | 22.42% |
| 2016 Q3 | 393.64 Million CNY | 15.62% |
| 2015 Q3 | 336.79 Million CNY | 3.29% |
| 2015 FY | 1.24 Billion CNY | 14.17% |
| 2015 Q4 | 352.05 Million CNY | 4.53% |
| 2015 Q2 | 326.05 Million CNY | 39.94% |
| 2015 Q1 | 232.99 Million CNY | -23.2% |
| 2014 Q4 | 303.37 Million CNY | 4.03% |
| 2014 FY | 1.09 Billion CNY | 22.44% |
| 2014 Q1 | 216.21 Million CNY | -11.82% |
| 2014 Q2 | 281.78 Million CNY | 30.32% |
| 2014 Q3 | 291.62 Million CNY | 3.49% |
| 2013 Q3 | 224.67 Million CNY | -5.2% |
| 2013 Q4 | 245.2 Million CNY | 9.14% |
| 2013 FY | 892.69 Million CNY | 60.51% |
| 2013 Q1 | 185.82 Million CNY | -16.25% |
| 2013 Q2 | 236.99 Million CNY | 27.54% |
| 2012 Q1 | 67.6 Million CNY | -10.29% |
| 2012 Q4 | 221.88 Million CNY | 35.5% |
| 2012 Q2 | 102.9 Million CNY | 52.23% |
| 2012 Q3 | 163.75 Million CNY | 59.12% |
| 2012 FY | 556.15 Million CNY | 170.22% |
| 2011 Q1 | 31.11 Million CNY | -26.06% |
| 2011 FY | 205.81 Million CNY | 60.53% |
| 2011 Q3 | 53.93 Million CNY | 18.75% |
| 2011 Q4 | 75.35 Million CNY | 39.73% |
| 2011 Q2 | 45.41 Million CNY | 45.96% |
| 2010 Q2 | 29.12 Million CNY | 9.24% |
| 2010 FY | 128.2 Million CNY | 44.0% |
| 2010 Q3 | 30.83 Million CNY | 5.84% |
| 2010 Q1 | 26.66 Million CNY | 0.0% |
| 2010 Q4 | 42.08 Million CNY | 36.5% |
| 2009 FY | 89.03 Million CNY | 74.91% |
| 2008 FY | 50.9 Million CNY | 111.29% |
| 2007 FY | 24.09 Million CNY | 0.0% |